what is the biotech company on teh nasdaq that has the highest chance of its srates going up tenfold

There isn’t a reliable way to name one Nasdaq biotech stock most likely to go up tenfold, because that kind of move is highly speculative and usually depends on clinical-trial success, FDA decisions, cash runway, and sentiment shifts. Based on the public material I could verify, names that have been discussed for outsized upside include CG Oncology (NASDAQ: CGON) , Sellas Life Sciences (NASDAQ: SLS) , and Evommune (EVMN) , but each is still a high-risk biotech story rather than a dependable tenbagger pick.

What the data suggests

• CG Oncology (CGON) has recent momentum around a rolling BLA filing and bladder-cancer data, which is the kind of catalyst investors watch for in biotech.
• Sellas Life Sciences (SLS) has been highlighted in social-media-driven “10x” discussions, but even the source notes skeptics see more modest upside scenarios than a full tenfold move.

• Evommune (EVMN) was described as an under-the-radar biotech with decade-scale 10x potential if its autoimmune programs keep progressing.

Practical read

If your goal is the highest chance of a tenfold gain, the honest answer is that no Nasdaq biotech can be labeled that way with confidence. The closest thing is usually a company with a strong late-stage catalyst, a manageable balance sheet, and a valuation that still leaves room for a major rerating, but biotech outcomes remain binary and can fall apart fast.

Names to watch

• CGON : near-term regulatory catalyst.
• SLS : speculative, story-driven upside.
• EVMN : longer-horizon program potential.

TL;DR: If forced to pick the most plausible current “10x-style” Nasdaq biotech from the material I found, CG Oncology (CGON) looks like the most catalyst-backed name, while SLS and EVMN are more speculative upside bets.